サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1482313

子宮頸癌診断の市場規模 - 診断検査・年齢層・エンドユーザー別 - 地域別展望・競合戦略・セグメント予測 (～2033年)

Cervical Cancer Diagnostic Market Size- By Diagnostic Test, By Age Group, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033
出版日: | 発行: SPER Market Research Pvt. Ltd. | ページ情報: 英文 205 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.13円
子宮頸癌診断の市場規模 - 診断検査・年齢層・エンドユーザー別 - 地域別展望・競合戦略・セグメント予測 (～2033年)
出版日: 2024年04月29日
発行: SPER Market Research Pvt. Ltd.
ページ情報: 英文 205 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

世界の子宮頸癌診断の市場規模は、2033年にかけて5.28％のCAGRで推移し、133億7,000万米ドルの規模に成長すると予測されています。

2020年のCOVID-19は市場に大きな影響を与え、子宮頸癌診断の市場も医療サービスの混乱により課題に直面しました。COVID-19の症例管理に注力した結果、子宮頸癌診断件数は減少し、多数の医療施設が緊急性のない手術やスクリーニングを遅らせたため、定期検査を受ける女性の数に影響が出ました。

当レポートでは、世界の子宮頸癌診断の市場を調査し、市場概要、市場影響因子および市場機会の分析、市場規模の推移・予測、各種区分・地域/主要国別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 促進要因・抑制要因・機会・課題の分析
  • COVID-19の市場への影響

第5章 市場変数と見通し

  • SWOT分析
  • PESTEL分析
  • ポーターのファイブフォース分析
  • ヒートマップ分析

第6章 競合情勢

  • 製造拠点の分布・販売エリア・製品タイプ
  • M&A・提携・製品発売・協力

第7章 世界の子宮頸癌診断市場：診断検査別

  • 世界市場の規模・シェア・予測
  • パップスメア検査
  • HPV検査
  • 生検・ECC
  • 膣鏡検査
  • その他

第8章 世界の子宮頸癌診断市場：年齢層別

  • 世界市場の規模・シェア・予測
  • 20～40歳
  • 40歳以上

第9章 世界の子宮頸癌診断市場：エンドユーザー別

  • 世界市場の規模・シェア・予測
  • 病院
  • 専門クリニック
  • 癌・放射線治療センター
  • 診断センター
  • その他

第10章 世界の子宮頸癌診断市場の予測

  • 市場規模・市場シェア

第11章 世界の子宮頸癌診断市場：地域別

  • 市場規模・市場シェアの推移・予測
  • アジア太平洋
  • 欧州
  • 中東・アフリカ
  • 北米
  • ラテンアメリカ

第12章 企業プロファイル

  • Zilico
  • Siemens Healthineers AG
  • QIAGEN NV
  • Abbott Laboratories
  • Becton, Dickinson and Co.
  • Quest Diagnostics Inc.
  • F. Hoffmann-La Roche Ltd.
  • Guided Therapeutics
  • Hologic Inc.
  • Bio-Rad Laboratories Inc.
  • その他

第13章 略語一覧

第14章 参考リンク

第15章 総論

第16章 調査範囲

目次
Product Code: HLCA2447

Cervical Cancer Diagnostic Market Introduction and Overview

According to SPER market research, 'Cervical Cancer Diagnostic Market Size- By Diagnostic Test, Age Group, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033' state that the Global Cervical Cancer Diagnostic Market is predicted to reach 13.37 billion by 2033 with a CAGR of 5.28%.

Cervical cancer is a type of cancer that originates in the cervix. The thinner, lower end of the uterus is known as the cervix (womb). The uterus and vagina are connected via the cervix. Typically, it develops gradually over time. Dysplasia occurs in the cells of the cervix before cervical cancer develops. It begins to reveal aberrant cells in the cervical tissue. If the abnormal cells are not cleared or killed, they may eventually grow into malignant cells that proliferate and spread throughout the cervix and surrounding tissues.

The 2020 COVID-19 pandemic had a significant impact on the market. Cervical cancer diagnostics market faced challenges because to the COVID-19 pandemic-related disruptions in healthcare services. Cervical cancer diagnostics decreased as a result of the focus on COVID-19 case management. A significant number of healthcare facilities delayed non-urgent surgeries and screenings, which in turn affected the number of women receiving routine testing.

Scope of the Report:

Report Metric Details

Market size available for years 2020-2033

Base year considered 2023

Forecast period 2024-2033

Segments covered By Diagnostic Test, By Age Group, By End User

Regions covered North America, Asia-Pacific, Latin America, Middle East & Africa and Europe

Companies Covered Zilico, Siemens Healthineers AG, QIAGEN NV, Abbott Laboratories, Becton, Dickinson and Co, Quest Diagnostics Inc, F. Hoffmann-La Roche Ltd, Guided Therapeutics, Hologic Inc, Bio-Rad Laboratories.

Global Cervical Cancer Diagnostic Market Segmentation:

By Diagnostic Test: Based on the Diagnostic Test, Global Cervical Cancer Diagnostic Market is segmented as, Pap Smear Tests, HPV Test, Biopsy and ECC, Colposcopy Tests, Others.

By End User: Based on the End User, Global Cervical Cancer Diagnostic Market is segmented as; Hospitals, Speciality Clinics, Cancer and Radiation Therapy Centers, Diagnostic Centers, Others.

By Region: This research also includes data for North America, Asia-Pacific, Latin America, Middle East & Africa and Europe.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1. Research data source
    • 2.1.1. Secondary Data
    • 2.1.2. Primary Data
    • 2.1.3. SPER's internal database
    • 2.1.4. Premium insight from KOL's
  • 2.2. Market size estimation
    • 2.2.1. Top-down and Bottom-up approach
  • 2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
    • 4.1.4. Challenges
  • 4.2. COVID-19 Impacts of the Global Cervical Cancer Diagnostic Market.

5. Market variable and outlook

  • 5.1. SWOT Analysis
    • 5.1.1. Strengths
    • 5.1.2. Weaknesses
    • 5.1.3. Opportunities
    • 5.1.4. Threats
  • 5.2. PESTEL Analysis
    • 5.2.1. Political Landscape
    • 5.2.2. Economic Landscape
    • 5.2.3. Social Landscape
    • 5.2.4. Technological Landscape
    • 5.2.5. Environmental Landscape
    • 5.2.6. Legal Landscape
  • 5.3. PORTER's Five Forces
    • 5.3.1. Bargaining power of suppliers
    • 5.3.2. Bargaining power of buyers
    • 5.3.3. Threat of Substitute
    • 5.3.4. Threat of new entrant
    • 5.3.5. Competitive rivalry
  • 5.4. Heat Map Analysis

6. Competitive Landscape

  • 6.1. Global Cervical Cancer Diagnostic Market Manufacturing Base Distribution, Sales Area, Product Type
  • 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Cervical Cancer Diagnostic Market

7. Global Cervical Cancer Diagnostic Market, By Diagnostic Test (USD Million) 2020-2033

  • 7.1. Global Cervical Cancer Diagnostic Market Size, Share and Forecast, By Diagnostic Test, 2020-2026
  • 7.2. Global Cervical Cancer Diagnostic Market Size, Share and Forecast, By Diagnostic Test, 2027-2033
  • 7.3. Pap Smear Tests
  • 7.4. HPV Test
  • 7.5. Biopsy and ECC
  • 7.6. Colposcopy Tests
  • 7.7. Others

8. Global Cervical Cancer Diagnostic Market, By Age Group (USD Million) 2020-2033

  • 8.1. Global Cervical Cancer Diagnostic Market Size, Share and Forecast, By Age Group, 2020-2026
  • 8.2. Global Cervical Cancer Diagnostic Market Size, Share and Forecast, By Age Group, 2027-2033
  • 8.3. 20 to 40 years
  • 8.4. above 40 years

9. Global Cervical Cancer Diagnostic Market, By End User (USD Million) 2020-2033

  • 9.1. Global Cervical Cancer Diagnostic Market Size, Share and Forecast, By End User, 2020-2026
  • 9.2. Global Cervical Cancer Diagnostic Market Size, Share and Forecast, By End User, 2027-2033
  • 9.3. Hospitals
  • 9.4. Specialty Clinics
  • 9.5. Cancer and Radiation Therapy Centers
  • 9.6. Diagnostic Centers
  • 9.7. Others

10. Global Cervical Cancer Diagnostic Market Forecast, 2020-2033 (USD Million)

  • 10.1. Global Cervical Cancer Diagnostic Market Size and Market Share

11. Global Cervical Cancer Diagnostic Market, By Region, 2020-2033 (USD Million)

  • 11.1. Global Cervical Cancer Diagnostic Market Size and Market Share By Region (2020-2026)
  • 11.2. Global Cervical Cancer Diagnostic Market Size and Market Share By Region (2027-2033)
  • 11.3. Asia-Pacific
    • 11.3.1. Australia
    • 11.3.2. China
    • 11.3.3. India
    • 11.3.4. Japan
    • 11.3.5. South Korea
    • 11.3.6. Rest of Asia-Pacific
  • 11.4. Europe
    • 11.4.1. France
    • 11.4.2. Germany
    • 11.4.3. Italy
    • 11.4.4. Spain
    • 11.4.5. United Kingdom
    • 11.4.6. Rest of Europe
  • 11.5. Middle East and Africa
    • 11.5.1. Kingdom of Saudi Arabia
    • 11.5.2. United Arab Emirates
    • 11.5.3. Qatar
    • 11.5.4. South Africa
    • 11.5.5. Egypt
    • 11.5.6. Morocco
    • 11.5.7. Nigeria
    • 11.5.8. Rest of Middle-East and Africa
  • 11.6. North America
    • 11.6.1. Canada
    • 11.6.2. Mexico
    • 11.6.3. United States
  • 11.7. Latin America
    • 11.7.1. Argentina
    • 11.7.2. Brazil
    • 11.7.3. Rest of Latin America

12. Company Profile

  • 12.1. Zilico
    • 12.1.1. Company details
    • 12.1.2. Financial outlook
    • 12.1.3. Product summary
    • 12.1.4. Recent developments
  • 12.2. Siemens Healthineers AG
    • 12.2.1. Company details
    • 12.2.2. Financial outlook
    • 12.2.3. Product summary
    • 12.2.4. Recent developments
  • 12.3. QIAGEN NV
    • 12.3.1. Company details
    • 12.3.2. Financial outlook
    • 12.3.3. Product summary
    • 12.3.4. Recent developments
  • 12.4. Abbott Laboratories
    • 12.4.1. Company details
    • 12.4.2. Financial outlook
    • 12.4.3. Product summary
    • 12.4.4. Recent developments
  • 12.5. Becton, Dickinson and Co.
    • 12.5.1. Company details
    • 12.5.2. Financial outlook
    • 12.5.3. Product summary
    • 12.5.4. Recent developments
  • 12.6. Quest Diagnostics Inc.
    • 12.6.1. Company details
    • 12.6.2. Financial outlook
    • 12.6.3. Product summary
    • 12.6.4. Recent developments
  • 12.7. F. Hoffmann-La Roche Ltd.
    • 12.7.1. Company details
    • 12.7.2. Financial outlook
    • 12.7.3. Product summary
    • 12.7.4. Recent developments
  • 12.8. Guided Therapeutics
    • 12.8.1. Company details
    • 12.8.2. Financial outlook
    • 12.8.3. Product summary
    • 12.8.4. Recent developments
  • 12.9. Hologic Inc.
    • 12.9.1. Company details
    • 12.9.2. Financial outlook
    • 12.9.3. Product summary
    • 12.9.4. Recent developments
  • 12.10. Bio-Rad Laboratories Inc.
    • 12.10.1. Company details
    • 12.10.2. Financial outlook
    • 12.10.3. Product summary
    • 12.10.4. Recent developments
  • 12.11. Others

13. List of Abbreviations

14. Reference Links

15. Conclusion

16. Research Scope